首页> 美国卫生研究院文献>Oncotarget >Association between dose-volume parameters and acute bone marrow suppression in rectal cancer patients treated with concurrent chemoradiotherapy
【2h】

Association between dose-volume parameters and acute bone marrow suppression in rectal cancer patients treated with concurrent chemoradiotherapy

机译:同步放化疗治疗的直肠癌患者剂量参数与急性骨髓抑制的关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Concurrent chemoradiotherapy is one of the main treatments for rectal cancer. Bone marrow suppression is one of the critical factors that affect the progress of radiotherapy. We aimed to explore the association of incidence of acute bone marrow suppression with dose-volume parameters of pelvic bone marrow among rectal cancer patients with concurrent chemoradiotherapy. We retrospectively analyzed 50 rectal cancer patients for multivariate logistic regression analyses. Three subdomains of pelvic bone marrow (PBM), bilateral ilium (IBM), lower pelvis (LPBM), and lumbosacral spine (LSBM) were assigned. The radiation dose-volume parameters from the three subdomains and the whole pelvis were evaluated. Compared to Grade 0-1 leukopenia patients, ≥Grade 2 leukopenia patients exhibited significantly higher levels of IBM V20, V25, V35, mean dose (Dmean), LPBM V20, V25, V30, LSBM V15, PBM V15, V20, and PTV. The PBM V20 of ≥Grade 2 neutropenia patients was significantly higher than that of Grade 0-1 neutropenia patients. Multivariate analysis have demonstrated that IBM V20 and LSBM V15 were the independent factors affecting ≥ Grade 2 leukopenia. There is a correlation between low dose-volume parameters with acute bone marrow suppression. IBM V20, LSBM V15 and PBM V20 can be employed as the predictors of acute bone marrow suppression.
机译:同步放化疗是直肠癌的主要治疗方法之一。骨髓抑制是影响放射治疗进展的关键因素之一。我们的目的是探讨伴有放化疗的直肠癌患者急性骨髓抑制的发生率与骨盆骨髓剂量-体积参数的关系。我们回顾性分析了50例直肠癌患者,以进行多元logistic回归分析。分配了骨盆骨髓(PBM),双侧lium骨(IBM),下骨盆(LPBM)和腰s骨脊柱(LSBM)的三个子域。评估了来自三个子域和整个骨盆的辐射剂量-体积参数。与0-1级白细胞减少症患者相比,≥2级白细胞减少症患者表现出更高水平的IBM V20,V25,V35,平均剂量(Dmean),LPBM V20,V25,V30,LSBM V15,PBM V15,V20和PTV。 ≥2级中性粒细胞减少症患者的PBM V20显着高于0-1级中性粒细胞减少症患者的PBM V20。多变量分析表明,IBM V20和LSBM V15是影响≥2级白细胞减少症的独立因素。低剂量参数与急性骨髓抑制之间存在相关性。 IBM V20,LSBM V15和PBM V20可用作急性骨髓抑制的预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号